

Development of CD47/CD73 dual-target SAFAbody antibody therapy for the treatment of intractable solid cancer including triple-negative breast cancer

AprilBio



ONCOLOGY	Hit
Product Type	Immunoglobulin Product (Bispecific antibody)
Indication	1st indication : Solid cancer, triple-negative breast cancer
Target	CD73 & CD47
MoA(Mechanism of Action)	Activation of T cells and Immune cells in the tumor environment through inhibition of CD73 and CD47 signaling pathways.
Competitiveness	First In Class Dual inhibition of CD73 and CD47 signaling pathways
Development Stage	Hit
Route of Administration	Parenteral-Intravenous